CDK4 and non-small cell lung carcinoma: Recently, elevated levels of cyclin-dependent kinase 4 (CDK4), a key cell cycle promoting protein, have been observed in a BRAFV600E-mutant NSCLC patient, following dabrafenib and trametinib co-treatment, and the ectopic expression of CDK4 in patient-derived BRAFV600E-mutant cells conferred partial resistance to dabrafenib [111].